At the Crossroads: Addressing Fad Treatments and Evidence-Based Practice in Interdisciplinary Collaboration

Overview & Clinical Significance

Behavior analysts working within interdisciplinary teams encounter a persistent and ethically charged challenge: how to navigate situations where colleagues from other disciplines recommend, implement, or advocate for treatments that lack empirical support or that may cause harm. This challenge sits at the intersection of professional ethics, collaborative practice, and the commitment to evidence-based treatment that defines behavior analysis as a discipline.

The prevalence of fad treatments in autism intervention is well-documented. Despite decades of research establishing applied behavior analysis as a leading evidence-based approach for individuals with ASD, a range of alternative and complementary treatments continue to circulate in clinical and educational settings. Some of these are simply unproven — there is insufficient evidence to determine their efficacy or safety. Others have been directly evaluated and found to be ineffective. A smaller subset has been associated with potential harm, whether physical, psychological, or as a result of opportunity costs that divert resources from effective treatment.

For behavior analysts, the ethical obligation to deliver evidence-based services does not evaporate when working in interdisciplinary contexts. Code 2.09 of the BACB Ethics Code requires that behavior analysts recommend and implement only treatments with a demonstrated evidence base. Code 1.04 obligates practitioners to advocate for their clients' best interests, which includes speaking up when other team members propose interventions that do not meet evidential standards. Yet doing so requires navigating professional relationships, institutional hierarchies, and the genuine complexity of working across disciplinary boundaries — all while maintaining a collaborative and respectful posture.

This course addresses the difficult crossroads behavior analysts encounter in these moments and offers frameworks and strategies for navigating them effectively.

Background & Context

The term "fad treatment" in the context of autism intervention refers to practices that gain popularity without proportionate empirical support. These treatments often spread through parent advocacy communities, social media, and anecdotal reports of success before they are subjected to rigorous evaluation. The appeal of these treatments is understandable — families of autistic individuals are navigating an overwhelming landscape of options, often under significant time pressure and emotional urgency.

Interestingly, the proliferation of fad treatments is not limited to non-behavioral disciplines. Research suggests that behavior analysts themselves are implementing practices that lack adequate empirical grounding. This may occur through insufficient graduate training in evaluating evidence, through pressure from clients or administrators to implement novel approaches, or through exposure to training programs that present unproven methods alongside established ones without clear differentiation.

The interdisciplinary team context amplifies these challenges. Speech-language pathologists, occupational therapists, physicians, educators, and behavior analysts each bring disciplinary frameworks and evidence bases that may differ substantially. A treatment with a weak behavioral evidence base may have some support in occupational therapy literature, or a method recommended by a physician may have no RCT support but strong face validity within that medical culture. BCBAs entering these conversations must be prepared to engage with disciplinary differences in evidentiary standards without dismissing the perspectives of colleagues.

At the same time, the history of behavior analysis includes its own cautionary cases where widely implemented procedures were later found to be harmful or ineffective. This history calls for humility alongside rigor — behavior analysts should advocate for evidence-based practice not from a position of disciplinary superiority but from a genuine commitment to client welfare grounded in scientific reasoning.

Clinical Implications

The clinical implications of fad treatment implementation are significant. When a client's intervention hours are spent on unproven treatments, those hours are not being spent on evidence-based alternatives that could produce meaningful gains. This opportunity cost is a form of harm even when the fad treatment itself is benign — a concept sometimes called "passive harm" in the ethics literature.

For BCBAs supervising or consulting in settings where fad treatments are present, the first clinical implication is the need for a structured approach to treatment evaluation. When a new treatment is proposed by a team member, the behavior analyst should be equipped to evaluate it using an established framework: What is the quality and quantity of the evidence base? Has the treatment been evaluated in controlled studies with individuals similar to the client? What are the proposed mechanisms of action, and are they plausible given current behavioral science? Are there known risks or contraindications?

The second clinical implication involves documentation. When a client's team proposes or implements a treatment the BCBA has concerns about, those concerns should be documented. Under Code 1.04, behavior analysts are expected to advocate for their clients and to document cases where they cannot implement recommendations they believe are in the client's best interest. This documentation protects the client, the BCBA, and creates a record that may be useful if treatment outcomes need to be reviewed.

The third implication involves coaching and education. Many fad treatments persist because team members and caregivers have not been provided with accessible, respectful explanations of why evidence matters and what the evidence shows. BCBAs can serve an educational function on interdisciplinary teams without being condescending by sharing research literature in accessible formats, modeling evidence-based decision-making, and creating space for collaborative review of treatment options.

Ethical Considerations

The BACB Ethics Code provides clear guidance on evidence-based practice and the treatment of clients that directly applies to the fad treatment problem. Code 2.09 states that behavior analysts must recommend and implement scientifically supported treatments and must inform clients and caregivers when proposed treatments lack empirical support or may cause harm. This obligation persists regardless of whether the treatment is proposed by the BCBA or by another team member.

Code 1.01 requires behavior analysts to act with beneficence and non-maleficence — to actively promote client welfare and avoid harm. When a treatment is known to be ineffective, continuing to implement it or failing to advocate against it may constitute a violation of this principle. When a treatment carries known risks, the obligation to act is even stronger.

Code 1.06 addresses conflicts of interest and requires behavior analysts to avoid situations where personal, financial, or professional interests compromise their commitment to client welfare. This is relevant in interdisciplinary settings where BCBAs may feel social pressure to defer to senior colleagues or to maintain team harmony at the expense of client advocacy. Recognizing this potential conflict and proactively managing it is an ethical responsibility.

Code 6.01 addresses public statements and scientific integrity, requiring that behavior analysts accurately represent the evidence base when making public claims about treatments. When BCBAs observe colleagues or organizations making unsupported claims about fad treatments — whether in team meetings, marketing materials, or social media — they have an ethical obligation to consider how to respond in a way that protects the public's ability to make informed decisions about treatment.

Assessment & Decision-Making

When a BCBA encounters a proposed or existing fad treatment within an interdisciplinary team, a structured decision-making process can help navigate the situation effectively. The first step is to assess the treatment's evidence base systematically. This means going beyond a single narrative review to examine the type, quantity, and quality of available evidence. Single-case research designs, randomized controlled trials, systematic reviews, and meta-analyses carry different evidentiary weight, and the BCBA should understand these distinctions to make a well-reasoned argument.

The second step is to assess the risk profile of the proposed treatment. Not all unproven treatments carry the same level of concern. A treatment with no evidence but low potential for harm may warrant a different response than a treatment with no evidence and documented risks. The calculus of opportunity cost should also be factored in — even a low-risk, unproven treatment warrants concern if it consumes resources that could otherwise fund evidence-based services.

The third step is to assess the team and organizational context. Understanding who is championing the treatment, their role and authority within the team, the family's level of investment in the treatment, and the organization's stance on evidence-based practice helps the BCBA choose an appropriate intervention strategy. A direct conversation with a receptive colleague may be sufficient in one context; a more formal documentation or escalation process may be required in another.

Finally, BCBAs should develop a communication plan for raising concerns. This plan should be respectful of professional relationships, focused on client welfare rather than disciplinary rivalry, and grounded in specific evidence rather than general dismissal. Practicing these conversations — ideally in a supervision or peer consultation context — prepares practitioners for real-world encounters.

What This Means for Your Practice

BCBAs who work in interdisciplinary settings must develop what might be called "evidence advocacy" as a core clinical competency. This is the ability to evaluate treatment evidence accurately, communicate concerns respectfully and persuasively, and persist in advocacy when the stakes for the client are high — even when doing so is socially uncomfortable.

Developing a personal framework for evaluating fad treatments is a practical first step. This framework should include criteria for assessing the quality and quantity of evidence, a process for investigating the proposed mechanisms of action, and a decision tree for determining when and how to raise concerns within the team. Having this framework in place before encountering a specific fad treatment reduces the cognitive load in the moment and ensures that decisions are guided by principled reasoning rather than reactive responses.

Organizationally, BCBAs can advocate for systems-level supports for evidence-based practice, such as journal clubs, treatment evaluation protocols, and policies that require evidence review before new treatments are added to the service menu. These structural supports distribute the burden of evidence evaluation across the team rather than placing it entirely on individual practitioners.

Finally, practitioners should approach this work with compassion for families and colleagues. Families who have pursued fad treatments have done so out of love and hope for their children. Colleagues who recommend these treatments often genuinely believe they are helping. The BCBA's role is not to shame or dismiss but to provide grounded, evidence-based guidance that serves the client's best interests. This combination of ethical firmness and interpersonal compassion is what distinguishes effective evidence advocacy from mere disciplinary gatekeeping.